Tango Therapeutics (TNGX) Non Operating Income (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Non Operating Income of $3.3 million for Q1 2026, up 21.13% year-over-year from $2.7 million in Q1 2025, and up 6.41% quarter-over-quarter from $3.1 million in Q4 2025.
Tango Therapeutics (TNGX) Non Operating Income (2020 - 2026) Analysis & Trends
Tango Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 21.13% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $10.3 million (down 25.64% YoY), while the FY2025 annual figure was $9.7 million, down 37.43% from the prior year.
- Non Operating Income for Q1 2026 stood at $3.3 million, up from $3.1 million in the prior quarter.
- The five-year high for Non Operating Income was $4.4 million in Q1 2024, with the low at $171000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $2.7 million (2025), against an average of $2.6 million.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 2029.27% in 2022, then slumped 52.14% in 2025.
- Tango Therapeutics' Non Operating Income stood at $1.6 million in 2022, then jumped by 175.8% to $4.3 million in 2023, then dropped by 23.46% to $3.3 million in 2024, then dropped by 6.96% to $3.1 million in 2025, then gained by 6.41% to $3.3 million in 2026.
- Business Quant data shows TNGX's Non Operating Income at $3.3 million in Q1 2026, $3.1 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.45 Mn |
| Mar 31, 2026 | 3.26 Mn |
| Dec 31, 2025 | 3.06 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 4.07 Mn |
| Mar 31, 2024 | 4.38 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 3.39 Mn |
| Jun 30, 2023 | 2.60 Mn |
| Mar 31, 2023 | 2.28 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | 873,000.00 |
| Jun 30, 2022 | 347,000.00 |
| Mar 31, 2022 | 171,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Sep 30, 2021 | 41,000.00 |